Digest Network Come funziona
Network
/
Società
Al
Non verificato

Allay Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

4 comunicati stampa

Guarda tutti i comunicati
05/06/2025
Mercato del lavoro
Industria
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management
Fonte
Allay Therapeutics
Emittente
Business Wire
1.00
0
18/02/2025
Industria
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Allay Therapeutics Announces First Patients Dosed in Pivotal Phase 2b Registration Trial of ATX101 for Post-Surgical Pain Management After Knee Replacement Surgery
Fonte
Allay Therapeutics
Emittente
Business Wire
1.00
0
04/12/2024
Industria
Scienza
Biotecnologia
Sanità
Medicina - Varie
Salute
Igiene alimentare
Allay Therapeutics Receives FDA Breakthrough Therapy Designation (BTD) for ATX101 for the Treatment of Post-surgical Pain Following Total Knee Replacement Surgery
Fonte
Allay Therapeutics
Emittente
Business Wire
1.00
0
24/10/2024
Mercato del lavoro
Industria
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Allay Therapeutics Announces Expansion of Clinical and Scientific Advisory Boards to Support the Company’s Mission to Transform Post-Surgical Pain Management
Fonte
Allay Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0